ABIOGEN PHARMA: THE ITALIAN EXCELLENCE FROM FIVE GENERATIONS

Abiogen Pharma is one of the top 30 pharmaceutical companies in Italy, with over 350 employees and a turnover of about 160 milion € in 2016.

We focus our activities on some therapeutic areas such as: osteoarticular pathologies, pain management, dermatology, pediatric respiratory and diabetes.

In a scenario dominated by the processes of international concentration and integration, a Company strategy geared to change and flexibility is the most valid key to avoid a subordinate role to the globalizing policy of multinational groups. 


Innovation is also the key to flexibility and the pivot on which the Manufacturing activity operates at the state of the art production site opened in Pisa in 2001.


Moreover, Abiogen international expansion is one of the drivers that will support the company’s growth during the next years. Recent partnerships and alliances will allow Abiogen to export more and more “made in Italy” abroad.


Abiogen Pharma applied to the Italian successful model a flexible and innovative approach with a strong vocation for internationalization.


On the other hand It have pursued a strategy to make therapeutic solutions widely accessible, so that all the people can benefit from it.

Go to article: Home | Maximising ManufacturingGo to article: EditorialGo to article: Pfanstiehl Company InsightGo to article: PfanstiehlGo to article: ContentsGo to article: Daiichi JitsugyoGo to article: MedelpharmGo to article: NewsGo to article: B & W Tek Go to article: The Pharma Industry BriefingGo to article: Clinical trial transparency in the Americas Go to article: Malvern Panalytical Company InsightGo to article: Malvern PanalyticalGo to article: AralabGo to article: Gene and cell therapies: making manufacturing workGo to article: Capsugel Company InsightGo to article: Abiogen PharmaGo to article: Amazon and PillPack: an unstoppable pharmacy force?Go to article: GerresheimerGo to article: SGSGo to article: Cancer trials: making the most of biomarkersGo to article: SmartCAE Company InsightGo to article: SmartCAEGo to article: The highs and lows of hormone replacement therapyGo to article: EcocoolGo to article: LaudaGo to article: Verge Genomics: employing AI to improve drug discoveryGo to article: AirBridgeCargo Company InsightGo to article: AirBridgeCargoGo to article: Senn ChemicalsGo to article: What can life sciences firms really achieve with AI?Go to article: Pall BiotechGo to article: CBDepotGo to article: G.F.Go to article: Setting practical parameters for more accurate regulatory resourcingGo to article: TSS ABGo to article: MasterpackGo to article: HOF SonderanlagenbauGo to article: Röchling Medical NeuhausGo to article: Cannabis branding: Marketing an industry from the ground upGo to article: AlpexGo to article: PharmasolGo to article: EventsGo to article: AECO Telecom & Security SystemsGo to article: Event: CPhI WorldwideGo to article: HTI PlasticsGo to article: SanofiGo to article: Event: Outsourcing in Clinical Trials DACH 2018Go to article: Procaps Company InsightGo to article: ProcapsGo to article: Event: Big Data & Analytics for Pharma Summit Go to article: Wilhelm Haselmeier GmbH & Co KG Company InsightGo to article: Wilhelm Haselmeier GmbH & Co. KGGo to article: Next issueGo to article: Scandinavian Health Ltd. Company InsightGo to article: Scandinavian Health Ltd.Go to article: ILC Dover IncGo to article: Scilabware